Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Translation of human Δ133p53 mRNA and its targeting by antisense oligonucleotides complementary to the 5'-terminal region of this mRNA.

Tytuł:
Translation of human Δ133p53 mRNA and its targeting by antisense oligonucleotides complementary to the 5'-terminal region of this mRNA.
Autorzy:
Żydowicz-Machtel P; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Dutkiewicz M; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Swiatkowska A; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Gurda-Woźna D; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Ciesiołka J; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Źródło:
PloS one [PLoS One] 2021 Sep 07; Vol. 16 (9), pp. e0256938. Date of Electronic Publication: 2021 Sep 07 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Oligonucleotides, Antisense/*pharmacology
Protein Biosynthesis/*drug effects
Protein Isoforms/*genetics
Tumor Suppressor Protein p53/*genetics
Cell Survival/drug effects ; Codon, Initiator/antagonists & inhibitors ; HCT116 Cells ; Humans ; Introns/genetics ; Protein Isoforms/antagonists & inhibitors ; RNA, Messenger/antagonists & inhibitors ; Transcription Initiation Site/drug effects ; Tumor Suppressor Protein p53/antagonists & inhibitors
References:
Cell Death Differ. 2016 Sep 1;23(9):1515-28. (PMID: 27104929)
Sci Rep. 2018 Jan 24;8(1):1533. (PMID: 29367734)
FEBS Lett. 2010 Nov 5;584(21):4463-8. (PMID: 20937277)
PLoS One. 2015 Aug 26;10(8):e0136395. (PMID: 26308932)
Nat Commun. 2018 Jan 17;9(1):254. (PMID: 29343721)
Zebrafish. 2009 Dec;6(4):389-95. (PMID: 19916829)
J Mol Biol. 2020 Dec 4;432(24):166699. (PMID: 33157084)
Curr Gene Ther. 2019;19(3):172-196. (PMID: 31566126)
Biochemistry. 2011 Aug 23;50(33):7080-92. (PMID: 21770379)
Cancers (Basel). 2018 Aug 25;10(9):. (PMID: 30149602)
Cell Death Dis. 2018 Jul 3;9(7):750. (PMID: 29970881)
Cell Res. 2015 Mar;25(3):351-69. (PMID: 25698579)
BMC Bioinformatics. 2010 Mar 15;11:129. (PMID: 20230624)
Elife. 2016 Sep 15;5:. (PMID: 27630122)
Cell Death Differ. 2011 Feb;18(2):248-58. (PMID: 20689555)
Mamm Genome. 2018 Dec;29(11-12):831-842. (PMID: 29992419)
Nat Protoc. 2006;1(3):1610-6. (PMID: 17406453)
Gene. 2005 Nov 21;361:13-37. (PMID: 16213112)
J Pathol. 2018 Sep;246(1):77-88. (PMID: 29888503)
Mech Dev. 2018 Dec;154:82-90. (PMID: 29800619)
Int J Mol Sci. 2019 Dec 11;20(24):. (PMID: 31835844)
Adv Exp Med Biol. 2019;1157:133-177. (PMID: 31342441)
Cells. 2020 Jan 07;9(1):. (PMID: 31936122)
RNA Biol. 2013 Nov;10(11):1726-40. (PMID: 24418891)
Blood. 2011 May 12;117(19):5166-77. (PMID: 21411755)
Nucleic Acids Res. 2000 Apr 15;28(8):1785-93. (PMID: 10734198)
Cell Death Differ. 2017 Jun;24(6):1017-1028. (PMID: 28362428)
Microbiol Mol Biol Rev. 2011 Sep;75(3):434-67, first page of table of contents. (PMID: 21885680)
Methods. 2010 Oct;52(2):150-8. (PMID: 20554050)
Apoptosis. 2020 Dec;25(11-12):835-852. (PMID: 32955614)
Annu Rev Med. 2019 Jan 27;70:307-321. (PMID: 30691367)
Sci Rep. 2017 Dec 14;7(1):17587. (PMID: 29242583)
Int J Oncol. 2015 Dec;47(6):2153-64. (PMID: 26459801)
EMBO Rep. 2016 Nov;17(11):1542-1551. (PMID: 27702985)
Cell Death Dis. 2019 Aug 20;10(9):631. (PMID: 31431617)
Nucleic Acids Res. 2006 Mar 02;34(4):1270-80. (PMID: 16513845)
Oncogene. 2018 Apr;37(16):2150-2164. (PMID: 29371679)
Int J Mol Sci. 2019 Oct 29;20(21):. (PMID: 31671760)
RNA. 2006 May;12(5):851-61. (PMID: 16540693)
Genes Dev. 2005 Sep 15;19(18):2122-37. (PMID: 16131611)
Genes Dev. 2017 Sep 1;31(17):1717-1731. (PMID: 28982758)
Nat Cell Biol. 2009 Sep;11(9):1135-42. (PMID: 19701195)
PLoS One. 2015 Oct 29;10(10):e0141676. (PMID: 26513723)
Int J Mol Sci. 2019 Nov 29;20(23):. (PMID: 31795382)
Nat Struct Mol Biol. 2012 Jun 05;19(6):568-76. (PMID: 22664984)
J Cell Biol. 1989 Feb;108(2):229-41. (PMID: 2645293)
Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27. (PMID: 20094052)
Substance Nomenclature:
0 (Codon, Initiator)
0 (Oligonucleotides, Antisense)
0 (Protein Isoforms)
0 (RNA, Messenger)
0 (TP53 protein, human)
0 (Tumor Suppressor Protein p53)
Entry Date(s):
Date Created: 20210907 Date Completed: 20211116 Latest Revision: 20211116
Update Code:
20240105
PubMed Central ID:
PMC8423303
DOI:
10.1371/journal.pone.0256938
PMID:
34492050
Czasopismo naukowe
The p53 protein is expressed as at least twelve protein isoforms. Within intron 4 of the human TP53 gene, a P2 transcription initiation site is located and this transcript encodes two p53 isoforms: Δ133p53 and Δ160p53. Here, the secondary structure of the 5'-terminal region of P2-initiated mRNA was characterized by means of the SHAPE and Pb2+-induced cleavage methods and for the first time, a secondary structure model of this region was proposed. Surprisingly, only Δ133p53 isoform was synthetized in vitro from the P2-initiated p53 mRNA while translation from both initiation codons occurred after the transfection of vector-encoded model mRNA to HCT116 cells. Interestingly, translation performed in the presence of the cap analogue suggested that the cap-independent process contributes to the translation of P2-initiated p53 mRNA. Subsequently, several antisense oligonucleotides targeting the 5'-terminal region of P2-initiated p53 mRNA were designed. The selected oligomers were applied in in vitro translation assays as well as in cell lines and their impact on the Δ133p53 synthesis and on cell viability was investigated. The results show that these oligomers are attractive tools in the modulation of the translation of P2-initiated p53 mRNA through attacking the 5' terminus of the transcript. Since cell proliferation is also reduced by antisense oligomers that lower the level of Δ133p53, this demonstrates an involvement of this isoform in tumorigenesis.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies